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Abstract. – Introduction: Non-steroidal
anti-inflammatory drugs (NSAIDs) consumption
is strictly related to a high gastrointestinal and
cardiovascular mortality and morbidity rate.
Osteoarthritis Research Society International
(OARSI) recommendations in patients with
symptomatic hip or knee OA stated that NSAIDs
should be used at the lowest effective dose but
their long-term use should be avoided if possi-
ble. OARSI guidelines for the treatment of the
hip OA include the use of viscosupplementation,
which aims to restore physiological and rheo-
logical features of the synovial fluid. 
Objective: Aim of this multicentric, open and
retrospective study is to investigate if NSAID con-
sumption may be reduced by the use of ultra-
sound-guided intra-articular injection of several
hyaluronic acid (HA) products in hip joint adminis-
tered in patients affected by symptomatic hip OA.
Materials and Methods: Patients affected by
mono or bilateral symptomatic hip OA according
to American Rheumatology Association (ARA)
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criteria, radiological OA graded II-IV (Kellgren
and Lawrence) entered the study and were ad-
ministered with ultrasound-guided intra-articular
injection of hyaluronic acid products. As a pri-
mary endpoint, consumption of NSAIDs was
evaluated by recording the number of days a
month (range 0-30) the patient had used NSAID
during the previous month, reported at each vis-
it during the 24 months follow-up period. Sec-
ondary endpoints included further analysis for
subgroups of patients categorized for Lequesne
index score, Kellgren-Lawrence score, pain visu-
al analogue scale (VAS) score, ultrasound pat-
tern, age, hyaluronic acid used.
Results: 2343 patients entered the study. Re-
garding primary endpoint, the consumption of
NSAIDs was reduced of 48.2% at the third month
when compared with baseline values. This spar-
ing effect increased at 12th and 24th month with
a reduction respectively of 50% and 61% in com-
parison to baseline values. These differences
were statistically significant. 
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Conclusions: These data point out that intra-
articular hyaluronan preparations provide OA
pain relief and reduce NSAIDs consumption in a
large cohort of patients for a long period of fol-
low-up. Multiple courses of viscosupplementation
(vs) are required to maintain low dose of NSAID
consumption over time. NSAIDs consumption is
strictly related to an high gastrointestinal and car-
diovascular mortality and morbidity rate, instead
HA intra-articular treatment is well tolerated and
is associated with a low incidence of adverse ef-
fects. For these reasons further studies evaluat-
ing cost-effectiveness and cost-utility of VS in the
management of hip OA are required.
Key Words:
Hip, Osteoarthritis, NSAID, Ultrasound, Intra-articu-
lar injection, Hyaluronic acid.
Introduction
The prevalence of hip osteoarthritis (OA) is
about 3% to 6% in the Caucasian population and
has not changed in the past four decades1. In OA
hip involvement is the most frequent after knee
joint. 
Treatment designed for symptomatic hip OA
tries to reduce pain, maintain and/or improve
joint mobility, and limit disabilities. For this pur-
pose physicians use nonpharmacologic modali-
ties, including patient education and physical
and occupational therapy as well as pharmaco-
logic agents, both analgesics and non-steroidal
anti-inflammatory drugs (NSAIDs)2. For many
patients with OA the relief of mild-to-moderate
joint pain afforded by the simple analgesic ac-
etaminophen is comparable with that achievable
with a NSAID3. 
Wolfe et al4, in a meta-analysis (MA) of trials
comparing simple analgesics with NSAIDs in pa-
tients with knee OA noted that NSAID-treated pa-
tients had significantly greater improvement in
both pain at rest and pain on motion. In another
study5 diclofenac was statistically superior to ac-
etaminophen for both pain and function measured
with several validated outcome measures. Evi-
dence that NSAIDs are superior to acetaminophen
for pain relief in patients with lower limb joint OA
is available from another 2004 MA of randomised
controlled trials (RCTs). The clinical response rate
was higher (RR ¼ 1.24, 95% CI 1.08, 1.41) and
the number of patients preferring NSAIDs to aceta-
minophen was considerably greater (RR ¼ 2.46,
95% CI 1.51, 4.12)6.
NSAIDs drugs are very effective analgesics,
but along with the benefits they can cause some
harm as well, including gastrointestinal (GI)
bleeding7, renal failure8 and congestive heart fail-
ure9. The incidence of serious vascular events was
1% per annum in patients treated with COX-2 se-
lective agents compared with 0.9% in those on
traditional NSAIDs. A recent Cochrane system-
atic review of short-term RCTs10 shows that the
risk of NSAIDs caused serious GI complications,
such as peptic ulcers, perforations and bleeds in-
creasing with age, concurrent use of other med-
ications, and with the duration of therapy11.
These adverse effects can be severe and may re-
sult in death12. 
Recently OARSI recommandations13 in pa-
tients with symptomatic hip or knee OA stated
that non-steroidal anti-inflammatory drugs
(NSAIDs) should be used at the lowest effective
dose but their long-term use should be avoided if
possible. In patients with increased GI risk, ei-
ther a COX-2 selective agent or a non-selective
NSAID with coprescription of a proton pump in-
hibitor (PPI) or misoprostol for gastroprotection
may be considered. However, NSAIDs, including
both non-selective and COX-2 selective agents,
should be used with caution in patients with car-
diovascular (CV) risk factors.
OARSI guidelines for the treatment of the HIP
OA include the use of viscosupplementation
(VS), which aims to restore physiological and
rheological features of the synovial fluid. Visco-
supplementation is provided by the intra-articular
injection of hyaluronic acid (HA) products, a nat-
urally occurring polymer present in the synovial
fluid, or its derivatives. 
Even though intra-articular hip injection may
be performed “blindly”, nevertheless failure rate
is significant14. For such reasons, it has been sug-
gested to perform intra-articular injection of the
hip under radiological or ultrasound guidance.
This is one of the limiting factors for this prac-
tice, consequently few data exist in literature
about the viscosupplementation for the treatment
of hip OA15. Other Authors16,17, would rather use
ultrasound guidance. Even if there are some data
about efficacy of viscosupplementation of hip,
confirming a therapeutic effect similar to that
achieved in knee OA, data about cost effective-
ness are much more scarce. In all our researches
we have made use of NSAIDs consumption rate
as a pharmacoeconomical efficacy and validity
parameter showing its progressive and time sus-
tained percentage reduction. In order to confirm
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Esaote, Genoa Italy) was used with a sterile
biopsy guide attached. Hip joint was scanned by
means of an anterior parasagittal approach.
NSAIDs Consumption Evaluation
Consumption of NSAIDs was evaluated by
recording the number of days a month (range 0-
30) the patient had used NSAID during the previ-
ous month, reported at each visit during the fol-
low-up period. Each patient was followed-up
every three months after the first intra-articular
injection.
Primary Endpoint 
NSAIDs consumption reduction during 24
months observation time.
Secondary Endpoint 
Consumption of NSAIDs analized by sub-
groups related to:
1. Three HA more used (Synvisc, Hyalubrix,
Jointex);
2. Radiological grading of osteoarthritis accord-
ing to Kellegren-Lawrence classification by
grade II-III-IV;
3. Ultrasound grading according to our scoring
previously described, arranged in two classes:
group A composed by normal femoral head
profile (score 1); group B composed by flat-
tening of the femoral head profile, reduction of
the angle of the femoral head-neck junction
profile caused by initial deformity of the
femoral head and irregular femoral head pro-
file with osteophytes and/or bone erosions (re-
spectively score 2-3-4);
4. Patients’ age arranged in the following classes:
<50, 51-70, >71;
5. Algofunctional Lequesne21 score at the basal
evaluation arranged by low, medium and high
grade (<6, 6-10, >10);
6. Patients’ pain VAS score arranged in classes 0-
4, 5-8, 9-10.
Statistics
The average NSAIDs consumption obtained
for each control visit (3, 6, 9, 12, 15, 18, 21, and
24 months) has been compared with the others
and with the baseline value by parametric t-test
or Wilcoxon’s test. 
Moreover NSAIDs consumption has been
evaluated in different covariance subsets for
baseline and for each control visit by indipendent
t-test or Mann Whitney’s U test. The covariances
these preliminary data we perform the present
study to evaluate reduction of NSAID intake in a
large cohort of patients affected by hip OA after
intra-articular injection of Hialuronans under ul-
trasound monitoring, for a long period of fol-
lowup to suggest further study of cost-effective-
ness and cost-utility.
Subjects and Methods
Study Design
This is a multicentric, open and retrospective
study regarding NSAID consumption after US-
guided intra-articular injection of several
hyaluronic acid products in hip joint adminis-
tered in patients affected by symptomatic hip os-
teoarthritis. The Ethical Committee of S. Pietro
Hospital, Rome, Italy gave approval.
Patients Selection
Inclusion Criteria: Patients studied had mono
or bilateral symptomatic hip OA according to
American Rheumatology Association (ARA) cri-
teria18, radiological OA graded II-IV (Kellgren
and Lawrence19 assessed within the three previ-
ous months. Exclusions included use of anticoag-
ulant therapy (to avoid the possibility of intra-ar-
ticular or pericapsular haemorrhages) and ab-
sence of articular space at radiological or ultra-
sound assessment since a recent review of 80 pa-
tients with symptomatic knee OA treated with
hyaluronic acid, revealed that patients with a
complete collapse of joint space or bone loss
showed a poor clinical response.
Treatment
Injections were given according to symptoms
and clinical judgment; namely one or two in-
jections every six months according to patients’
clinical condition. One 2 ml ampule was used
with high molecular weight HA, e.g. Synvisc
and Euflexxa; two 2 ml ampule (a total of 4 ml)
with low or medium molecular weight HA, e.g.
Hyalgan, Hyalubrix 30 mg/ml, Jointex, and Or-
toial. 
Injection Technique
Patients underwent hip injection under control
of ultrasound as described previously17. Briefly,
patient was examined supine with the hip in in-
ternal-rotation of 15-20°. A 7 MHz linear or 3.5
MHz convex transducer (Star 256, Hitachi-
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considered are: age (categorized as <50, 50-70,
>70), pain VAS (categorized as <5, 5-8, >8 on a
0-10 scale), the Lequesne Index (<6, 6-10, >10),
the ultrasound score (0, 1, 2, 3), the Kellgren-
Lawrence Index1-4 and the administered drug1,3,5.
Results 
We enrolled 2343 patients affected by mono
(2140 pts) or bilateral (203 pts) OA of the hip ac-
cording to the ARA criteria. Patients’ demo-
graphics are shown in Table I. 
Primary Endpoint
We determined the average NSAIDs consump-
tion for each quarter from baseline to two years
follow up in 2343 patients.
Globally patients had taken NSAIDs for a
mean of 8.2 days a month before injection and
4.1 and 3.2 days a month respectively 12 and 24
months after treatment. The NSAID consumption
trend by each quarter is shown in Figure 1. There
is a significant statistical difference in NSAIDs
consumption between baseline and each time
point after the first injection for a followup of 24
months, while there is no significant statistical
difference in NSAIDs consumption between
every previous quarter.
The consumption of NSAIDs is reduced of
48.2% at the third month. This sparing effect has
increased at the 12th and 24th month with a reduc-
tion respectively of 50 and 61% in comparison to
the month before the first injection in patients
persisting under intra-articualr tratment. These
differences were statistically significant.
Secondary endpoint: To detect correlations be-
tween clinical features and NSAIDs consumption
reduction along time we performed an analysis
based upon different patients’ subsets in relation
with age, Lequesne index, VAS pain scale, ultra-
sound score, K/L radiological index and HA in-
jected.
Results of Subgroups 
Patients’ Age 
At baseline patients were divided in different
age groups: <50 (424 patients), 51-70 (1199 pa-
tients) and >71 (641 patients). In the three age-
groups there is a statistically significant differ-
ence in the average NSAIDs consumption among
the most distant ages (<50 vs >70 years) (Figure
2A). After 12 and 24 months class 1 patients
showed a reduction of 60% and 65%, while those
in class 2 of 49.4% and 52.3% and those in class
3 of 47.1% and 70.6%.
Algofunctional Lequesne Score 
Regarding Lequesne score, 531 patients fell
within 00-05 group (class 1) and respectively 983
within 06-10 (class 2) and 796 within >11 (class 3).
NSAIDs consumption in the three groups is statisti-
cally different when comparing baseline value with
values obtained at each control visit and in each
class (<6 vs 6-10 vs >10) (Figure 2B). After 12 and
24 months from baseline there is a reduction of
36.7% and 56.7% in class 1, of 42.1 and 56.6 in
class 2, of 52 and 55.8% in class 3 respectively.
Pain VAS
507 patients affered to 00-04 group 1 of pain
visual analogue scale (VAS) score, 1437 to 05-08
group 2 and 365 to 09-10 group 3. There is a sta-
tistically significant difference in the average
NSAIDs consumption among pain VAS >8 group
and the two others at baseline (Figure 2C). 
After 12 and 24 months from baseline there is
a reduction of 20.6% and 58.1% for the first, of
46.2% and 56.7% for the second, of 59.4% and
52.5% for third group. 
Kellegren-Lawrence
Radiological Classification
Patients affected by Kellegren-Lawrence (K/L)
radiological grade 1 or 2, 3 and 4 were respec-
tively 832, 762 and 246. There is no statistically
significant difference in NSAIDs consumption in
the three index groups (Figure 3A).
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Figure 1. NSAIDs consumption trend of each quarter.
Average NSAIDs consumption of each quarter
Months
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Figure 2. A, Average NSAIDs consumption of each quarter and group of age. B, Average NSAIDs consumption of each
quarter and LEQ group. C, Average NSAIDs consumption of each quarter and VAS group.
C, Average NSAIDs consumption of each quarter and VAS group
A, Average NSAIDs consumption of each quarter and group of age
B, Average NSAIDs consumption of each quarter and LEQ group
Quarters
Quarters
Quarters
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Figure 3. A, Average NSAIDs consumption of each quarter and radiological KL classification. B, Average NSAIDs con-
sumption of each quarter and drug used. C, Average NSAIDs consumption of each quarter and ultrasound score.
C, Mean NSAIDs consumption of rate for ultrasound pattern-based groups of patients
A, Average NSAIDs consumption of each quarter and Kl radiological classification
B, Average NSAIDs consumption of each quarter and drug
Quarters
Quarters
Quarters
HA used 
Characteristics of three analized hyaluronic
acid products are shown in Table II. A total of
878 patients were treated with Synvisc at the
dose of 1 injection of one vial (2 ml) every six
month. 503 patients were treated with Hyalubrix
60 mg at the dose of 1 injection of one vial (4
ml) every six month. 307 patients were treated
with Jointex 32 mg at the dose of 1 injection of
two vials (4 ml) every six month. 
If the symptoms got worse each patient might
be subject to an extra injection of the same prod-
uct three months after precedent injection. There
is no statistically significant difference in
NSAIDs consumption among the three HA prod-
ucts examined over study time (Figure 3B).
Ultrasound Score 
Patients presenting US score of 1, 2, 3 and 4
were respectively 329, 178, 203 and 338. There
is no statistically significant difference in
NSAIDs consumption among the four ultrasound
score levels (Figure 3C).
Number of Injections
The total number of injections administered
under ultrasound guidance during the 24-month
study was 13,233 and patients received a mean of
5.6 injections. Figure 1 summarizes the number
of patients per different injections numbers. 
Discussion
This study is based on the “Italian national
registry of hip ultrasound guided intrarticular
treatment” data. 
The registry was filled in with daily clinical
experiences of physicians specialized in different
medical fields such as Internal medicine, Radiol-
ogy, Rheumatology, Physical medicine, Sports
medicine. It reflects real life treatment data20.
Our data, deduced from 2343 patients, suggest
that hip ultrasound guided intra-articular treat-
ment in symptomatic hip osteoarthritis may
cause an important NSAIDs consumption reduc-
tion, measured as number of days during each
month the patient takes NSAIDs to control pain.
Our findings show that average NSAIDs con-
sumption abruptly falls in the first three months
comparing with percentage of the whole number
which reaches a permanent level until 24 months.
There were no significative differences in the av-
erage NSAIDs consumption comparing each
quarter with the previous one (p>0.05). Anyway,
NSAIDs consumption reduction is 50 and 61% at
12th and 24th month respectively. This result is
obtained by the recurring treatment every at least
six months, with the chance of one or two extra
injections if needed. This approach allows thera-
py customization and the achievement of the
lowest effective dosage. Actually every quarter
following starting time the average NSAIDs con-
sumption is significantly below than the baseline
one (p<0.0001). These data get on well with our
previous ones obtained by shorter as well as
smaller studies21-23:
In VS of knee OA are similar data as well. In a
systematic review Waddell24 reported that cost
effectiveness of intra-articular hyaluronans has
been demonstrated and it can also be realised
with reduction of NSAID medication use.
NSAIDs consumption reduction may entail
clinical and social consequences. It is known that
use of NSAIDs appear to be correlated with in-
creased morbidity and mortality. 
In 2009, Gislason et al25 reported of 36,354
patients hospitalized with a primary congestive
heart failure (CHF) diagnosis and discharged re-
ceiving a prescription for an NSAID. A total of
60,974 patients (56.9%) died during the course
of the study. 
NSAIDs were associated with a higher risk of
mortality, ranging from a hazard ratio of 1.22 for
naproxen to 2.08 for diclofenac. The increased
risk in mortality appeared to be dose-dependent.
There was also a consistent relationship between
NSAID use and higher rates of subsequent death.
On the contrary no death has been associated
with VS of both hip and knee. HA products have
been shown to have an excellent safety and effi-
cacy profile as a viscosupplement for the OA of
the knee and hip17,21-23,26-28. 
Moreover NSAIDs consumption reduction ob-
tained by VS might decrease risk with an expo-
nential model.
From an economical point of view NSAIDs
consumption reduction implies not only decrease
of direct costs but of indirect ones as well, relat-
ed to PPI or misoprostol prescription for gastro-
protection or to hospitalization for gastric or car-
diovascular adverse events. 
Considering hospitalization and co-prescribing
costs in the UK, it has been estimated that the
National Health Service spends on average £ 251
milion per year on NSAID induced GI side-ef-
fects11. A survey of the literature looking at these
31
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costs throughout the world reveals similar sce-
narios elsewhere. It should be regarded as public
health problem. In the UK there are about 12,000
emergency GI admissions per year attributable to
NSAIDs29. 
Recent studies suggest that hospital admis-
sions for congestive heart failure (CHF) are also
increased appreciably in people taking NSAIDS.
In a case-control study of patients admitted to
hospital with their first episode of CHF, Henry et
al30 showed a relative risk of 2.3 (95% confi-
dence interval 1.2 to 4.4) in users of non-
steroidal anti-inflammatory drugs (defined as use
in the previous 7 days). The burden of illness re-
sulting from NSAID related congestive heart fail-
ure may exceed that resulting from gastrointesti-
nal tract damage, approaching the same levels of
morbidity and mortality. NSAIDs use increases
with age8 and the proportion of elderly patients
taking NSAIDs has been estimated at as much as
25%31. Recently in a rewiev COX-2 selective
NSAIDs were found to be similar to non-selec-
tive NSAIDs for the symptomatic relief of OA
and to provide superior GI tolerability (the ma-
jority of evidence is in patients with OA). Al-
though COX-2 selective NSAIDs offer protection
against serious GI events, the amount of evidence
for this protective effect varied considerably
across individual drugs. The volume of trial evi-
dence with regard to cardiovascular safety also
varied substantially between COX-2 selective
NSAIDs. Increased risk of MI compared to non-
selective NSAIDs was observed among those
drugs with greater volume of evidence in terms
of exposure in patient-years.
Conclusions
Intra-articular treatment with hyaluronic acid
and its derivatives represents nowadays an im-
portant opportunity of hip osteoarthritis manage-
ment. Many intra-articular hyaluronan formula-
tions are available at this very moment differing
each other in their physical properties, duration
of effect and treatment schedules. Our findings
point out not only that intra-articular hyaluronan
preparations provide a reduction in NSAIDs con-
sumption indicating hip OA pain relief. Since hip
OA is a chronic disease multiple courses are re-
quired and this allows a better therapy cus-
tomization for each patient a personalized man-
agement improving therapy effectiveness.
NSAIDs consumption is strictly related to an
high gastrointestinal and cardiovascular mortality
and morbidity rate differently from HA intra-ar-
ticular treatment that is well tolerated and is as-
sociated with a low incidence of adverse effects,
usually localised to the injected joint. Local ad-
verse events associated with intra-articular
hyaluronan products are typically mild to moder-
ate in severity, benign and transient.
The cost effectiveness of intra-articular
hyaluronan has not been completely demonstrat-
ed because of the limited number of studies. Be-
cause different intra-articular hyaluronan formu-
lations require different numbers of injections
and office visits not all intra-articular hyaluronan
formulations may be equally cost effective over
time. The present study shows a reduction of
NSAID intake in a large cohort of patients for a
long period of followup after hip viscosupple-
mentation. We suggest further study of cost-ef-
fectiveness and cost-utility as in knee OA32.
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